Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2022 - 2025)

Historic Other Non-Current Assets for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $3.2 million.

  • Zentalis Pharmaceuticals' Other Non-Current Assets rose 2204.04% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 2204.04%. This contributed to the annual value of $4.4 million for FY2024, which is 3521.56% down from last year.
  • Zentalis Pharmaceuticals' Other Non-Current Assets amounted to $3.2 million in Q3 2025, which was up 2204.04% from $3.2 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $6.8 million during Q4 2023, with a 5-year trough of $2.6 million in Q2 2022.
  • In the last 4 years, Zentalis Pharmaceuticals' Other Non-Current Assets had a median value of $2.7 million in 2024 and averaged $3.2 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first surged by 15953.56% in 2023, then tumbled by 3521.56% in 2024.
  • Over the past 4 years, Zentalis Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $2.6 million in 2022, then surged by 159.54% to $6.8 million in 2023, then crashed by 35.22% to $4.4 million in 2024, then dropped by 27.42% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $3.2 million for Q2 2025, and $3.3 million during Q1 2025.